{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T04:59:00Z","timestamp":1648961940110},"reference-count":14,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.3892\/ol.2013.1184","type":"journal-article","created":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T11:34:06Z","timestamp":1360236846000},"page":"1382-1384","source":"Crossref","is-referenced-by-count":2,"title":["Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report"],"prefix":"10.3892","volume":"5","author":[{"given":"JOS\u00c9 MIGUEL","family":"JURADO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IRENE","family":"ZARCOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAYTE","family":"DELGADO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ISABEL","family":"BLANCAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARTA","family":"LEGER\u00c9N","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JOS\u00c9 LUIS","family":"GARC\u00cdA-PUCHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,2,7]]},"reference":[{"key":"key20180108092557_b1-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108092557_b2-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108092557_b3-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180108092557_b4-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Global ARCC trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"key20180108092557_b5-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s10555-012-9354-z","article-title":"Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action","volume":"31","author":"Gonz\u00e1lez Larriba","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"key20180108092557_b6-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180108092557_b7-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12032-009-9220-1","article-title":"Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma","volume":"27","author":"Gerullis","year":"2010","journal-title":"Med Oncol"},{"key":"key20180108092557_b8-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/0284186X.2011.589404","article-title":"Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma","volume":"51","author":"Lamm","year":"2012","journal-title":"Acta Oncol"},{"key":"key20180108092557_b9-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"key20180108092557_b10-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdq320","article-title":"Temsirolimus in VEGF-refractory metastatic renal cell carcinoma","volume":"22","author":"Mackenzie","year":"2011","journal-title":"Ann Oncol"},{"key":"key20180108092557_b11-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/cncr.24241","article-title":"Sequential therapy in renal cell carcinoma","volume":"115","author":"Escudier","year":"2009","journal-title":"Cancer"},{"key":"key20180108092557_b12-ol-05-04-1382","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)34327-1","article-title":"Temsirolimus vs Sorafenib as Second Line Therapy in Metastatic Renal Cell Carcinoma: Phase 3 Results from the INTORSECT Trial","author":"Hutson","year":"2012"},{"key":"key20180108092557_b13-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/CAD.0b013e32833760bf","article-title":"Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma","volume":"21","author":"Rodriguez-Pascual","year":"2010","journal-title":"Anticancer Drugs"},{"key":"key20180108092557_b14-ol-05-04-1382","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2010.01.003","article-title":"Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma","volume":"36","author":"Schmidinger","year":"2010","journal-title":"Cancer Treat Rev"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2013.1184\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T01:12:20Z","timestamp":1595380340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2013.1184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,7]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,2,7]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.3892\/ol.2013.1184"],"URL":"https:\/\/doi.org\/10.3892\/ol.2013.1184","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,7]]}}}